Usually, iron(III) compounds are dissolved in the stomach at a sufficiently acid pH value and thus made available for absorption. In the process, the human organism utilizes both divalent as well as trivalent iron ions. The absorption rate is regulated by the organism depending on the iron requirement and the size of the iron store.
The iron level is regulated by absorption, with the absorption rate of the iron present in food being between 6 and 12% in the case of iron deficiency, the absorption rate is up to 25%. In a healthy human adult, the normal daily loss of iron of about 1 mg is usually replaced via the daily food intake. Generally, blood loss can significantly reduce the iron level since about 1 mg iron is lost per 2 ml blood.
by desquamation of skin and epithelial cells, is low increased iron loss occurs, for example, during menstrual hemorrhage in women. The daily iron requirement of an adult human is between 0.5 to 1.5 mg per day, infants and women during pregnancy require 2 to 5 mg of iron per day. The amount of iron of about 25 mg required daily for erythropoiesis is thus provided for the main part. This high regenerative capacity is achieved by macrophages phagocytizing the ageing erythrocytes, lysing them and thus recycling the iron thus obtained for the iron metabolism. Since these erythrocytes have only a limited lifespan (75-150 days), new ones have to be formed constantly and old ones eliminated (over 2 million erythrocytes are being formed per second). On average, the human body contains 4 to 5 g iron, with it being present in enzymes, in hemoglobin and myoglobin, as well as depot or reserve iron in the form of ferritin and hemosiderin.Īpproximately half of this iron, about 2 g, is present as heme iron, bound in the hemoglobin of the erythrocytes. In the human body, the element iron is of great importance for oxygen transport, oxygen uptake, cell functions such as mitochondrial electron transport, and ultimately for the entire energy metabolism. The released iron is taken up via the intestine, in particular via specific transport systems (DMT-1, ferroportin, transferrin, transferrin receptors), transferred into the circulation and thereby conveyed to the appropriate tissues and organs. The balance of the iron metabolism is in this case primarily regulated on the level of iron recovery from hemoglobin of ageing erythrocytes and the duodenal absorption of dietary iron. Iron is an essential trace element for almost all organisms and is relevant in particular with respect to growth and the formation of blood. The invention relates to iron(III)-3-hydroxy-isonicotinamide complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias. The applicant for Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias patent is This invention was filed in the category of
Was filed with the USPTO on Thursday, March 27, 2014. The Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias patent Patent Application Number is a unique ID to identify the Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias mark in USPTO. – by the United States Patent and Trademark Office (USPTO). The Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias patent was assigned a FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS - Patent Information By Thomas Bark